Sanara MedTech Inc. announced that its BIASURGE® Advanced Surgical Solution has been granted an Innovative Technology contract by Vizient, the largest provider-driven healthcare performance improvement company in the U.S. The contract follows a rigorous review by client-led councils composed of hospital experts, who evaluated products submitted through Vizient’s Innovative Technology Program for their ability to enhance clinical care, patient and worker safety, or business operations. BIASURGE’s no-rinse irrigation formulation, optimized for pH, viscosity and osmolality, demonstrated superior wound-cleansing efficiency and broad-spectrum antimicrobial effectiveness compared to standard saline irrigation, leading to the council’s recommendation and contract award effective January 1, 2026.

Under the new agreement, Vizient’s client base—which represents over $156 billion in annual purchasing volume and includes academic medical centers, pediatric facilities, community hospitals and integrated delivery networks—will gain access to BIASURGE on pre-negotiated pricing and terms. This streamlined contracting process, operated outside the traditional competitive bid cycle, is expected to accelerate adoption of BIASURGE across hundreds of healthcare facilities. Sanara MedTech’s President and CEO Seth Yon highlighted that the contract provides immediate visibility to procurement teams and clinical decision-makers, potentially reducing the sales cycle from months to weeks while driving volume growth in the North American surgical tissue repair market.

Following the contract announcement, Sanara MedTech received an upgrade to a Zacks Rank #1 (Strong Buy), reflecting increased confidence in the company’s earnings trajectory as it begins to monetize the Vizient agreement. Trading volume spiked by 56% versus its 30-day average, with 58,532 shares exchanged in mid-day activity. Recent institutional transactions include a 351.7% stake increase by BNP Paribas Financial Markets and new positions established by MetLife Investment Management, signaling growing investor interest. Analysts now forecast that Sanara MedTech will post improved revenue growth in fiscal 2026 as BIASURGE penetration in Vizient member facilities ramps up.